GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abivax SA (STU:2X1) » Definitions » PensionAndRetirementBenefit

Abivax (STU:2X1) PensionAndRetirementBenefit : €0.76 Mil (As of Dec. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Abivax PensionAndRetirementBenefit?

Abivax's PensionAndRetirementBenefit for the quarter that ended in Dec. 2024 was €0.76 Mil.

Abivax's quarterly PensionAndRetirementBenefit increased from Jun. 2023 (€0.59 Mil) to Dec. 2023 (€0.63 Mil) and increased from Dec. 2023 (€0.63 Mil) to Dec. 2024 (€0.76 Mil).

Abivax's annual PensionAndRetirementBenefit increased from Dec. 2022 (€0.61 Mil) to Dec. 2023 (€0.63 Mil) and increased from Dec. 2023 (€0.63 Mil) to Dec. 2024 (€0.76 Mil).


Abivax PensionAndRetirementBenefit Historical Data

The historical data trend for Abivax's PensionAndRetirementBenefit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abivax PensionAndRetirementBenefit Chart

Abivax Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
PensionAndRetirementBenefit
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.69 0.61 0.63 0.76

Abivax Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Dec24
PensionAndRetirementBenefit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.61 0.59 0.63 0.76

Abivax PensionAndRetirementBenefit Calculation

PensionAndRetirementBenefit is the carrying amount as of the balance sheet date of the portion of the obligations recognized for the various benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement.


Abivax Business Description

Industry
Traded in Other Exchanges
Address
7-11 boulevard Haussmann, Paris, FRA, 75009
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.

Abivax Headlines

No Headlines